Clinical Trials Logo

Clinical Trial Summary

To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03901729
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 2
Start date May 29, 2019
Completion date May 21, 2021

See also
  Status Clinical Trial Phase
Completed NCT03456856 - A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. Phase 4
Completed NCT02301689 - SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
Completed NCT04915118 - A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF
Completed NCT02200822 - Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Phase 4
Recruiting NCT04149743 - HEMOTAG® Assessment for Short-term Outcomes of Heart Failure N/A
Recruiting NCT05652218 - REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT) N/A
Completed NCT01936649 - Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Phase 4
Completed NCT02127307 - Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up. N/A